Ayoola Gomih, MD
Urology · Merrillville, INNPI 1831117522
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $16,088 of the $20,187 with a category attached, or 79.7%. Great Lakes Medical Services, LLC accounts for 83.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $9,984 and has fallen 92.2% since, to $777 in 2025.
Across 134 payments — averaging $150.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Great Lakes Medical Services, LLC$17K
- Astellas Pharma US Inc$1K
- Boston Scientific$586
- Endo Pharmaceuticals Inc.$570
- Pfizer$352
- Endo USA, Inc.$188
- plus $522 from 9 others
What the payments were for
- Speaking & faculty fees$8294%
- Travel & lodging$4602%
- Food & beverage$2,16911%
- Education$6413%
- Ownership interest$16,08880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Great Lakes Medical Services, LLC | 12 | $16,917 |
| Astellas Pharma US Inc | 42 | $1,051 |
| Boston Scientific | 6 | $586 |
| Endo Pharmaceuticals Inc. | 26 | $570 |
| Pfizer | 14 | $352 |
| Endo USA, Inc. | 9 | $188 |
| Sumitomo Pharma America, Inc. | 7 | $137 |
| Myovant Sciences Inc. | 6 | $117 |
| Progenics Pharmaceuticals, Inc. | 3 | $65 |
| Abiomed | 1 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $38 |
| Cardinal Health 414 LLC | 2 | $33 |
| Profound Medical Corp. | 1 | $23 |
| Bayer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,187 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 49 | $511,767 |
| OrgovyxRelugolix | 87 | $238,958 |
| Lupron DepotLeuprolide Acetate | 15 | $91,106 |
| MyrbetriqMirabegron | 80 | $72,090 |
| Mirabegron ErMirabegron | 13 | $9,197 |
| Bethanechol Chloride | 77 | $4,147 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $2,803 |
| Tamsulosin Hcl | 324 | $2,788 |
| Oxybutynin Chloride ErOxybutynin Chloride | 75 | $2,755 |
| Bicalutamide | 58 | $2,259 |
| Finasteride | 210 | $2,099 |
| Dutasteride | 37 | $1,061 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $703 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 37 | $470 |
| Oxybutynin Chloride | 11 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,051 | $583,857129 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $137 | $238,95887 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.
Other urology in Merrillville
- Manoj RaoMerrillville$36K
- Bruce YalowitzMerrillville$11K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Eugene ConeGreenwood$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.